These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

87 related items for PubMed ID: 17228857

  • 1. Receptor-mediated delivery of antigens to dendritic cells: anticancer applications.
    Proudfoot O, Apostolopoulos V, Pietersz GA.
    Mol Pharm; 2007; 4(1):58-72. PubMed ID: 17228857
    [Abstract] [Full Text] [Related]

  • 2. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
    Tacken PJ, de Vries IJ, Torensma R, Figdor CG.
    Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
    [Abstract] [Full Text] [Related]

  • 3. Mutual helper effect in copulsing of dendritic cells with 2 antigens: a novel approach for improvement of dendritic-based vaccine efficacy against tumors and infectious diseases simultaneously.
    Shojaeian J, Jeddi-Tehrani M, Dokouhaki P, Mahmoudi AR, Ghods R, Bozorgmehr M, Nikoo S, Bayat AA, Akhondi MM, Ostadkarampour M, Rezania S, Zarnani AH.
    J Immunother; 2009 May; 32(4):325-32. PubMed ID: 19342973
    [Abstract] [Full Text] [Related]

  • 4. Enhancement of dendritic cell-based vaccine potency by anti-apoptotic siRNAs targeting key pro-apoptotic proteins in cytotoxic CD8(+) T cell-mediated cell death.
    Kim JH, Kang TH, Noh KH, Bae HC, Kim SH, Yoo YD, Seong SY, Kim TW.
    Immunol Lett; 2009 Jan 29; 122(1):58-67. PubMed ID: 19135479
    [Abstract] [Full Text] [Related]

  • 5. Presentation of tumour antigens by dendritic cells and challenges faced.
    Robson NC, Hoves S, Maraskovsky E, Schnurr M.
    Curr Opin Immunol; 2010 Feb 29; 22(1):137-44. PubMed ID: 20116984
    [Abstract] [Full Text] [Related]

  • 6. Dendritic cells in cancer immunotherapy.
    Gunzer M, Grabbe S.
    Crit Rev Immunol; 2001 Feb 29; 21(1-3):133-45. PubMed ID: 11642600
    [Abstract] [Full Text] [Related]

  • 7. Dendritic cell-based cancer immunotherapies.
    Fujii S, Takayama T, Asakura M, Aki K, Fujimoto K, Shimizu K.
    Arch Immunol Ther Exp (Warsz); 2009 Feb 29; 57(3):189-98. PubMed ID: 19479202
    [Abstract] [Full Text] [Related]

  • 8. Advances in specific immunotherapy for prostate cancer.
    Kiessling A, Füssel S, Wehner R, Bachmann M, Wirth MP, Rieber EP, Schmitz M.
    Eur Urol; 2008 Apr 29; 53(4):694-708. PubMed ID: 18061335
    [Abstract] [Full Text] [Related]

  • 9. Splenic dendritic cells pulsed with Ixodes ricinus tick saliva prime naive CD4+T to induce Th2 cell differentiation in vitro and in vivo.
    Mejri N, Brossard M.
    Int Immunol; 2007 Apr 29; 19(4):535-43. PubMed ID: 17344202
    [Abstract] [Full Text] [Related]

  • 10. The use of dendritic cells in cancer immunotherapy.
    Nencioni A, Grünebach F, Schmidt SM, Müller MR, Boy D, Patrone F, Ballestrero A, Brossart P.
    Crit Rev Oncol Hematol; 2008 Mar 29; 65(3):191-9. PubMed ID: 18055210
    [Abstract] [Full Text] [Related]

  • 11. The 'kiss of death' by dendritic cells to cancer cells.
    Chan CW, Housseau F.
    Cell Death Differ; 2008 Jan 29; 15(1):58-69. PubMed ID: 17948029
    [Abstract] [Full Text] [Related]

  • 12. Dendritic cells and their role in cancer immunotherapy.
    Jalili A.
    Iran J Immunol; 2007 Sep 29; 4(3):127-44. PubMed ID: 17767012
    [Abstract] [Full Text] [Related]

  • 13. Preparation of fully activated dendritic cells capable of priming tumor-specific cytotoxic T lymphocytes in patients with metastatic cancer using penicillin-killed streptococcus pyogenes (OK432) and anti-CD40 antibody.
    Kontani K, Teramoto K, Ozaki Y, Sawai S, Tezuka N, Ishida H, Kajino K, Fujino S, Yamauchi A, Taguchi O, Kannagi R, Yokomise H, Ogasawara K.
    Oncol Rep; 2007 Apr 29; 17(4):895-902. PubMed ID: 17342333
    [Abstract] [Full Text] [Related]

  • 14. Listeria monocytogenes activated dendritic cell based vaccine for prevention of experimental tumor in mice.
    Khamisabadi M, Arab S, Motamedi M, Khansari N, Moazzeni SM, Gheflati Z, Hadjati J.
    Iran J Immunol; 2008 Mar 29; 5(1):36-44. PubMed ID: 18319523
    [Abstract] [Full Text] [Related]

  • 15. Nonspecific CD4(+) T cells with uptake of antigen-specific dendritic cell-released exosomes stimulate antigen-specific CD8(+) CTL responses and long-term T cell memory.
    Hao S, Yuan J, Xiang J.
    J Leukoc Biol; 2007 Oct 29; 82(4):829-38. PubMed ID: 17626150
    [Abstract] [Full Text] [Related]

  • 16. Cancer vaccines for established cancer: how to make them better?
    Andrews DM, Maraskovsky E, Smyth MJ.
    Immunol Rev; 2008 Apr 29; 222():242-55. PubMed ID: 18364006
    [Abstract] [Full Text] [Related]

  • 17. Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.
    Gigante M, Mandic M, Wesa AK, Cavalcanti E, Dambrosio M, Mancini V, Battaglia M, Gesualdo L, Storkus WJ, Ranieri E.
    J Immunother; 2008 Apr 29; 31(3):254-62. PubMed ID: 18317362
    [Abstract] [Full Text] [Related]

  • 18. [Dendritic cells--and their possible applications in cancer therapy].
    Agger R, Hokland ME.
    Ugeskr Laeger; 2000 Aug 14; 162(33):4377-81. PubMed ID: 10962960
    [Abstract] [Full Text] [Related]

  • 19. Targeted antigen delivery and activation of dendritic cells in vivo: steps towards cost effective vaccines.
    Tacken PJ, Figdor CG.
    Semin Immunol; 2011 Feb 14; 23(1):12-20. PubMed ID: 21269839
    [Abstract] [Full Text] [Related]

  • 20. Unique functions of splenic CD8alpha+ dendritic cells during infection with intracellular pathogens.
    Neuenhahn M, Busch DH.
    Immunol Lett; 2007 Dec 15; 114(2):66-72. PubMed ID: 17964665
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.